GLP-1 prior authorization for commercial plans
Customize your policy alerts
Sign up for all Florida Blue policy alerts
Know when Florida Blue releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Florida Blue commercial plan coverage and prior authorization requirements for GLP-1 medications used to treat type 2 diabetes, and lists preferred and non-covered GLP-1 products. Applies to providers submitting pharmacy prior authorization requests for affected members.
Effective April 1, 2025, Florida Blue requires prior authorization on file for members on prescribed GLP-1 therapy under commercial plans.
Coverage Criteria for GLP-1 Agents
Initial authorization criteria
Covered when ALL of the following are met
Florida Blue commercial plans only cover GLP-1 drugs for type 2 diabetes; requests lacking documentation will be denied
Providers must submit documentation of trial and failure to demonstrate medical necessity
Respond promptly to requests for additional information; urgent inquiries require response within 48 hours
Medications prescribed for weight management, including GLP‑1 products marketed for weight loss such as Wegovy, Zepbound, and Saxenda, are excluded from coverage under Florida Blue commercial plans. Authorization requests submitted for these weight‑loss indications will be denied and members are responsible for payment. Trulicity is also listed as not covered for this drug class.
Use of GLP‑1 receptor agonists for non–type 2 diabetes indications (for example, weight loss or weight‑management therapy) is considered not covered / medically unnecessary under Florida Blue commercial plans; requests for these indications will be denied.
Initial Therapy Criteria
Initial therapy criteria
Initial approval requires documented prior therapy and diagnosis.
Authorization requests will be denied if the patient is not a type 2 diabetic or lacks clinical documentation
Required prior to GLP-1 approval
Continuation Therapy Requirements
Continuation therapy requirement
Members currently on a prescribed GLP-1 therapy will be required to have a prior authorization on file starting April 1, 2025.
Operational requirement effective date April 1, 2025
Provider Actions and Prior Authorization Instructions
Prior authorization required for GLP-1 (effective 4/1/2025)
Prior authorization must be obtained for GLP-1 medications for members with Florida Blue commercial plans beginning April 1, 2025. Submit the prior authorization request to Prime Therapeutics via CoverMyMeds and include all required information in a single complete submission to avoid processing delays.
- Operational start date: April 1, 2025
- Submission pathway: Prime Therapeutics via CoverMyMeds
- Submit one complete prior authorization request (do not submit duplicates)
Document prior trial and failure of metformin or insulin
Providers must document a prior trial and failure of metformin, metformin combination drugs, or insulin before a GLP-1 will be approved.
- Document trial and clinical failure of metformin, other metformin combination drugs, or insulin in the submitted records
Provide clinical diagnosis and prior-therapy evidence; respond to info requests
Submit clinical documentation confirming a diagnosis of type 2 diabetes and evidence the patient has tried and failed metformin (or metformin combination drugs) or insulin; respond promptly to requests for additional information.
- Include clinical records that verify a type 2 diabetes diagnosis
- Include documentation of prior medication trials and failure
- If Prime Therapeutics requests more information, respond promptly (48 hours for urgent pharmacy requests)
Denial risk for missing type 2 diabetes documentation
Authorization requests will be denied if the patient is not a type 2 diabetic or if the request lacks clinical documentation supporting a type 2 diabetes diagnosis.
- Ensure submitted records clearly document the type 2 diabetes diagnosis to avoid denial
Denial for weight-loss indications (excluded agents)
Requests for GLP-1 medications intended for weight loss (for example, Wegovy, Zepbound, Saxenda) are excluded from coverage and will be denied; patients seeking these agents for weight management will be responsible for out-of-pocket payment.
- Do not submit prior authorization requests for GLP-1 products when the indication is weight loss or weight management
- Refer patients to Florida Blue wellness and weight management programs as appropriate
Coding and Submission Pathway
| No codes listed |
Definitions and Exclusions
Step Therapy Requirements
| Step | Requirement | Failure criteria |
|---|---|---|
| 1 | Documented trial of metformin, a metformin combination product, or insulin prior to initiation of a GLP-1 agent | Medical record documentation showing trial and failure (insufficient response, intolerance, or contraindication) of metformin, metformin combination drug, or insulin |
Background
GLP‑1 receptor agonists are indicated for glycemic control in type 2 diabetes. Florida Blue limits coverage of GLP‑1 agents to FDA‑indicated use for type 2 diabetes and requires prior authorization for covered uses. Medications used specifically for weight management are outside the scope of coverage for commercial plans and will be denied; providers should direct members to available wellness and weight‑management programs offered by Florida Blue as an alternative resource.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.